Drug intelligence / Profile preview

SUL-267

Development stage: Preclinical
Lead developer: Sulfateq
Modality: Small Molecules

Overview

SUL-267 is a preclinical-stage small molecule developed by Sulfateq for the treatment of Pulmonary Arterial Hypertension (PAH). The compound is part of a platform of molecules inspired by natural hibernation and mitochondrial stress-coping mechanisms. SUL-267 specifically targets mitochondrial dysfunction, aiming to restore cellular energy balance and resilience in the context of PAH. The exact molecular target has not been disclosed by the company, but the mechanism of action is centered on protecting mitochondria from stress-induced damage and maintaining cellular health under pathological conditions.

Beyond the preview

Go deeper on SUL-267.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SUL-267.

Explore the full profile